News & Events - Organovo, Inc.
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
Home - Organovo, Inc.
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases Read …
Pipeline - Organovo, Inc.
Organovo expects FXR314 to have a widening set of therapeutic applications as we advance our knowledge and our science. In addition to FXR314, Organovo is planning to begin medicinal chemistry in 2023 to create a novel drug for another, as yet undisclosed, target.
Organovo Highlights FXR314 Combination Therapy Potential and …
Nov 8, 2023 · In both Organovo’s proprietary 3D human models and in preclinical animal models of disease, FXR314 treatment demonstrates a reduction in the disruption of the intestinal lining, which protects against bacteria penetrating into the intestinal wall.
Who We Are - Organovo, Inc.
Organovo creates human models of inflammatory bowel disease (IBD) using our 3D tissue technologies and uses them to understand, invent, and develop the best drug therapies for ulcerative colitis and Crohn’s disease.
About - Organovo, Inc.
© 2025 Organovo Holdings Inc. 11555 Sorrento Valley Road, Suite 100 San Diego, CA 92121
Norman Staskey - Organovo, Inc.
Corporate Headquarters. 11555 Sorrento Valley Road, Suite 100, San Diego, CA 92121 Tel: (858) 224-1000
Investor Overview - Organovo Holdings, Inc.
Organovo is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. The company’s lead molecule, FXR314, is on the path for Phase 2 investigation in inflammatory bowel disease and has potential application in metabolic ...
Media Coverage - Organovo, Inc.
Merck 'bio-inks' deal to use Organovo's 3D printed liver for preclinical studies
Organovo to Participate in the H.C. Wainwright Global Investment ...
Sep 8, 2023 · Organovo is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. The company’s lead molecule, FXR314, is on the path for Phase 2 investigation in inflammatory bowel disease and has potential application in metabolic ...